ID   PUR2_HUMAN              Reviewed;        1010 AA.
AC   P22102; A8K945; A8KA32; D3DSF3; D3DSF4; O14659; Q52M77;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Trifunctional purine biosynthetic protein adenosine-3;
DE   Includes:
DE     RecName: Full=Phosphoribosylamine--glycine ligase;
DE              EC=6.3.4.13;
DE     AltName: Full=Glycinamide ribonucleotide synthetase;
DE              Short=GARS;
DE     AltName: Full=Phosphoribosylglycinamide synthetase;
DE   Includes:
DE     RecName: Full=Phosphoribosylformylglycinamidine cyclo-ligase;
DE              EC=6.3.3.1;
DE     AltName: Full=AIR synthase;
DE              Short=AIRS;
DE     AltName: Full=Phosphoribosyl-aminoimidazole synthetase;
DE   Includes:
DE     RecName: Full=Phosphoribosylglycinamide formyltransferase;
DE              EC=2.1.2.2;
DE     AltName: Full=5'-phosphoribosylglycinamide transformylase;
DE     AltName: Full=GAR transformylase;
DE              Short=GART;
GN   Name=GART; Synonyms=PGFT, PRGS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=2147474; DOI=10.1093/nar/18.22.6665;
RA   Aimi J., Qiu H., Williams J., Zalkin H., Dixon J.E.;
RT   "De novo purine nucleotide biosynthesis: cloning of human and avian
RT   cDNAs encoding the trifunctional glycinamide ribonucleotide
RT   synthetase-aminoimidazole ribonucleotide synthetase-glycinamide
RT   ribonucleotide transformylase by functional complementation in E.
RT   coli.";
RL   Nucleic Acids Res. 18:6665-6672(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT
RP   ILE-421.
RC   TISSUE=Testis, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 357-432, AND VARIANT ILE-421.
RX   PubMed=9224613; DOI=10.1093/nar/25.15.3118;
RA   Kan J.L.C., Moran R.G.;
RT   "Intronic polyadenylation in the human glycinamide ribonucleotide
RT   formyltransferase gene.";
RL   Nucleic Acids Res. 25:3118-3123(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 709-1010.
RX   PubMed=2183217; DOI=10.1073/pnas.87.8.2916;
RA   Schild D., Brake A.J., Kiefer M.C., Young D., Barr P.J.;
RT   "Cloning of three human multifunctional de novo purine biosynthetic
RT   genes by functional complementation of yeast mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2916-2920(1990).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-350, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-440; THR-682;
RP   SER-796 AND SER-802, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 808-1010 IN COMPLEX WITH
RP   SUBSTRATE.
RX   PubMed=12450384; DOI=10.1021/bi020522m;
RA   Zhang Y., Desharnais J., Greasley S.E., Beardsley G.P., Boger D.L.,
RA   Wilson I.A.;
RT   "Crystal structures of human GAR Tfase at low and high pH and with
RT   substrate beta-GAR.";
RL   Biochemistry 41:14206-14215(2002).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 808-1010 IN COMPLEX WITH
RP   FORMYLTETRAHYDROFOLATE ANALOG.
RX   PubMed=12755606; DOI=10.1021/bi034219c;
RA   Zhang Y., Desharnais J., Marsilje T.H., Li C., Hedrick M.P.,
RA   Gooljarsingh L.T., Tavassoli A., Benkovic S.J., Olson A.J.,
RA   Boger D.L., Wilson I.A.;
RT   "Rational design, synthesis, evaluation, and crystal structure of a
RT   potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-
RT   dideazaacyclic-5,6,7,8-tetrahydrofolic acid.";
RL   Biochemistry 42:6043-6056(2003).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 808-1010 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS.
RX   PubMed=16026156; DOI=10.1021/bi050307g;
RA   Dahms T.E., Sainz G., Giroux E.L., Caperelli C.A., Smith J.L.;
RT   "The apo and ternary complex structures of a chemotherapeutic target:
RT   human glycinamide ribonucleotide transformylase.";
RL   Biochemistry 44:9841-9850(2005).
CC   -!- CATALYTIC ACTIVITY: ATP + 5-phospho-D-ribosylamine + glycine = ADP
CC       + phosphate + N(1)-(5-phospho-D-ribosyl)glycinamide.
CC   -!- CATALYTIC ACTIVITY: ATP + 2-(formamido)-N(1)-(5-phospho-D-
CC       ribosyl)acetamidine = ADP + phosphate + 5-amino-1-(5-phospho-D-
CC       ribosyl)imidazole.
CC   -!- CATALYTIC ACTIVITY: 10-formyltetrahydrofolate + N(1)-(5-phospho-D-
CC       ribosyl)glycinamide = tetrahydrofolate + N(2)-formyl-N(1)-(5-
CC       phospho-D-ribosyl)glycinamide.
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       5-amino-1-(5-phospho-D-ribosyl)imidazole from N(2)-formyl-N(1)-(5-
CC       phospho-D-ribosyl)glycinamide: step 2/2.
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-
CC       ribose 1-diphosphate: step 2/2.
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide from N(1)-(5-
CC       phospho-D-ribosyl)glycinamide (10-formyl THF route): step 1/1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P22102-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P22102-2; Sequence=VSP_005517;
CC   -!- SIMILARITY: In the N-terminal section; belongs to the GARS family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the central section; belongs to the AIR synthase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the GART family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X54199; CAA38119.1; -; mRNA.
DR   EMBL; AK292560; BAF85249.1; -; mRNA.
DR   EMBL; AK292897; BAF85586.1; -; mRNA.
DR   EMBL; CH471079; EAX09826.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09827.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09828.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09829.1; -; Genomic_DNA.
DR   EMBL; BC038958; AAH38958.1; -; mRNA.
DR   EMBL; BC093641; AAH93641.1; -; mRNA.
DR   EMBL; BC101565; AAI01566.1; -; mRNA.
DR   EMBL; AF008653; AAB70812.1; -; Genomic_DNA.
DR   EMBL; M32082; AAA60077.1; -; mRNA.
DR   CCDS; CCDS13627.1; -. [P22102-1]
DR   CCDS; CCDS13628.1; -. [P22102-2]
DR   PIR; S12616; AJHUPR.
DR   RefSeq; NP_000810.1; NM_000819.4. [P22102-1]
DR   RefSeq; NP_001129477.1; NM_001136005.1. [P22102-1]
DR   RefSeq; NP_001129478.1; NM_001136006.1. [P22102-1]
DR   RefSeq; NP_780294.1; NM_175085.2. [P22102-2]
DR   RefSeq; XP_005260998.1; XM_005260941.1. [P22102-1]
DR   RefSeq; XP_006724052.1; XM_006723989.1. [P22102-1]
DR   RefSeq; XP_006724053.1; XM_006723990.1. [P22102-1]
DR   RefSeq; XP_011527828.1; XM_011529526.1. [P22102-1]
DR   UniGene; Hs.473648; -.
DR   PDB; 1MEJ; X-ray; 2.00 A; A/B/C=810-1010.
DR   PDB; 1MEN; X-ray; 2.23 A; A/B/C=810-1010.
DR   PDB; 1MEO; X-ray; 1.72 A; A=808-1010.
DR   PDB; 1NJS; X-ray; 1.98 A; A/B=808-1010.
DR   PDB; 1RBM; X-ray; 2.30 A; A/B=808-1010.
DR   PDB; 1RBQ; X-ray; 2.10 A; A/B/C/D=808-1010.
DR   PDB; 1RBY; X-ray; 2.10 A; A/B/C/D=808-1010.
DR   PDB; 1RBZ; X-ray; 2.10 A; A/B=808-1010.
DR   PDB; 1RC0; X-ray; 2.05 A; A/B=808-1010.
DR   PDB; 1RC1; X-ray; 2.25 A; A/B=808-1010.
DR   PDB; 1ZLX; X-ray; 2.20 A; A=808-1010.
DR   PDB; 1ZLY; X-ray; 2.07 A; A=808-1010.
DR   PDB; 2QK4; X-ray; 2.45 A; A/B=1-430.
DR   PDB; 2V9Y; X-ray; 2.10 A; A/B=467-794.
DR   PDB; 4EW1; X-ray; 1.52 A; A=810-1010.
DR   PDB; 4EW2; X-ray; 1.60 A; A=808-1010.
DR   PDB; 4EW3; X-ray; 1.70 A; A=808-1010.
DR   PDB; 4ZYT; X-ray; 1.70 A; A=808-1010.
DR   PDB; 4ZYU; X-ray; 1.95 A; A=808-1010.
DR   PDB; 4ZYV; X-ray; 2.05 A; A=808-1010.
DR   PDB; 4ZYW; X-ray; 2.05 A; A=808-1010.
DR   PDB; 4ZYX; X-ray; 1.65 A; A=808-1010.
DR   PDB; 4ZYY; X-ray; 1.85 A; A=808-1010.
DR   PDB; 4ZYZ; X-ray; 1.60 A; A=808-1010.
DR   PDB; 4ZZ0; X-ray; 1.65 A; A=808-1010.
DR   PDB; 4ZZ1; X-ray; 1.35 A; A=808-1010.
DR   PDB; 4ZZ2; X-ray; 1.45 A; A=808-1010.
DR   PDB; 4ZZ3; X-ray; 2.50 A; A=808-1010.
DR   PDB; 5J9F; X-ray; 2.10 A; A=808-1010.
DR   PDBsum; 1MEJ; -.
DR   PDBsum; 1MEN; -.
DR   PDBsum; 1MEO; -.
DR   PDBsum; 1NJS; -.
DR   PDBsum; 1RBM; -.
DR   PDBsum; 1RBQ; -.
DR   PDBsum; 1RBY; -.
DR   PDBsum; 1RBZ; -.
DR   PDBsum; 1RC0; -.
DR   PDBsum; 1RC1; -.
DR   PDBsum; 1ZLX; -.
DR   PDBsum; 1ZLY; -.
DR   PDBsum; 2QK4; -.
DR   PDBsum; 2V9Y; -.
DR   PDBsum; 4EW1; -.
DR   PDBsum; 4EW2; -.
DR   PDBsum; 4EW3; -.
DR   PDBsum; 4ZYT; -.
DR   PDBsum; 4ZYU; -.
DR   PDBsum; 4ZYV; -.
DR   PDBsum; 4ZYW; -.
DR   PDBsum; 4ZYX; -.
DR   PDBsum; 4ZYY; -.
DR   PDBsum; 4ZYZ; -.
DR   PDBsum; 4ZZ0; -.
DR   PDBsum; 4ZZ1; -.
DR   PDBsum; 4ZZ2; -.
DR   PDBsum; 4ZZ3; -.
DR   PDBsum; 5J9F; -.
DR   ProteinModelPortal; P22102; -.
DR   SMR; P22102; -.
DR   BioGrid; 108888; 65.
DR   IntAct; P22102; 23.
DR   MINT; MINT-1143007; -.
DR   STRING; 9606.ENSP00000371236; -.
DR   BindingDB; P22102; -.
DR   ChEMBL; CHEMBL3972; -.
DR   DrugBank; DB03546; 10-CF3C(OH)2-DDACTHF.
DR   DrugBank; DB02236; Glycinamide Ribonucleotide.
DR   DrugBank; DB00642; Pemetrexed.
DR   iPTMnet; P22102; -.
DR   PhosphoSitePlus; P22102; -.
DR   SwissPalm; P22102; -.
DR   BioMuta; GART; -.
DR   DMDM; 131616; -.
DR   EPD; P22102; -.
DR   MaxQB; P22102; -.
DR   PaxDb; P22102; -.
DR   PeptideAtlas; P22102; -.
DR   PRIDE; P22102; -.
DR   Ensembl; ENST00000361093; ENSP00000354388; ENSG00000159131. [P22102-2]
DR   Ensembl; ENST00000381815; ENSP00000371236; ENSG00000159131. [P22102-1]
DR   Ensembl; ENST00000381831; ENSP00000371253; ENSG00000159131. [P22102-1]
DR   Ensembl; ENST00000381839; ENSP00000371261; ENSG00000159131. [P22102-1]
DR   Ensembl; ENST00000571089; ENSP00000459532; ENSG00000262473.
DR   Ensembl; ENST00000573055; ENSP00000459391; ENSG00000262473.
DR   Ensembl; ENST00000575273; ENSP00000461700; ENSG00000262473.
DR   GeneID; 2618; -.
DR   KEGG; hsa:2618; -.
DR   UCSC; uc002yrx.4; human. [P22102-1]
DR   CTD; 2618; -.
DR   DisGeNET; 2618; -.
DR   GeneCards; GART; -.
DR   HGNC; HGNC:4163; GART.
DR   HPA; HPA002119; -.
DR   HPA; HPA005779; -.
DR   MIM; 138440; gene.
DR   neXtProt; NX_P22102; -.
DR   OpenTargets; ENSG00000159131; -.
DR   PharmGKB; PA28576; -.
DR   eggNOG; KOG0237; Eukaryota.
DR   eggNOG; KOG3076; Eukaryota.
DR   eggNOG; COG0150; LUCA.
DR   eggNOG; COG0151; LUCA.
DR   eggNOG; COG0299; LUCA.
DR   GeneTree; ENSGT00390000000292; -.
DR   HOVERGEN; HBG008333; -.
DR   InParanoid; P22102; -.
DR   KO; K11787; -.
DR   OMA; YRTDIAQ; -.
DR   OrthoDB; EOG091G026D; -.
DR   PhylomeDB; P22102; -.
DR   TreeFam; TF106368; -.
DR   BioCyc; MetaCyc:HS08358-MONOMER; -.
DR   BRENDA; 2.1.2.2; 2681.
DR   Reactome; R-HSA-73817; Purine ribonucleoside monophosphate biosynthesis.
DR   SIGNOR; P22102; -.
DR   UniPathway; UPA00074; UER00125.
DR   UniPathway; UPA00074; UER00126.
DR   UniPathway; UPA00074; UER00129.
DR   ChiTaRS; GART; human.
DR   EvolutionaryTrace; P22102; -.
DR   GenomeRNAi; 2618; -.
DR   PRO; PR:P22102; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000159131; -.
DR   CleanEx; HS_GART; -.
DR   ExpressionAtlas; P22102; baseline and differential.
DR   Genevisible; P22102; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004637; F:phosphoribosylamine-glycine ligase activity; TAS:Reactome.
DR   GO; GO:0004641; F:phosphoribosylformylglycinamidine cyclo-ligase activity; TAS:Reactome.
DR   GO; GO:0004644; F:phosphoribosylglycinamide formyltransferase activity; TAS:Reactome.
DR   GO; GO:0006189; P:'de novo' IMP biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0003360; P:brainstem development; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0006544; P:glycine metabolic process; IEA:Ensembl.
DR   GO; GO:0009113; P:purine nucleobase biosynthetic process; IEA:InterPro.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; TAS:Reactome.
DR   GO; GO:0010035; P:response to inorganic substance; IEA:Ensembl.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   GO; GO:0046654; P:tetrahydrofolate biosynthetic process; IEA:Ensembl.
DR   CDD; cd08645; FMT_core_GART; 1.
DR   CDD; cd02196; PurM; 1.
DR   Gene3D; 3.30.1330.10; -; 1.
DR   Gene3D; 3.30.1490.20; -; 1.
DR   Gene3D; 3.40.50.170; -; 1.
DR   Gene3D; 3.90.600.10; -; 1.
DR   Gene3D; 3.90.650.10; -; 1.
DR   HAMAP; MF_00741; AIRS; 1.
DR   HAMAP; MF_00138; GARS; 1.
DR   HAMAP; MF_01930; PurN; 1.
DR   InterPro; IPR010918; AIR_synth_C_dom.
DR   InterPro; IPR011761; ATP-grasp.
DR   InterPro; IPR013815; ATP_grasp_subdomain_1.
DR   InterPro; IPR002376; Formyl_transf_N.
DR   InterPro; IPR004607; GART.
DR   InterPro; IPR001555; GART_AS.
DR   InterPro; IPR016185; PreATP-grasp_dom.
DR   InterPro; IPR020561; PRibGlycinamid_synth_ATP-grasp.
DR   InterPro; IPR000115; PRibGlycinamide_synth.
DR   InterPro; IPR020560; PRibGlycinamide_synth_C-dom.
DR   InterPro; IPR020559; PRibGlycinamide_synth_CS.
DR   InterPro; IPR020562; PRibGlycinamide_synth_N.
DR   InterPro; IPR016188; PurM-like_N.
DR   InterPro; IPR004733; PurM_cligase.
DR   InterPro; IPR011054; Rudment_hybrid_motif.
DR   PANTHER; PTHR10520:SF42; PTHR10520:SF42; 1.
DR   Pfam; PF00586; AIRS; 1.
DR   Pfam; PF02769; AIRS_C; 1.
DR   Pfam; PF00551; Formyl_trans_N; 1.
DR   Pfam; PF01071; GARS_A; 1.
DR   Pfam; PF02843; GARS_C; 1.
DR   Pfam; PF02844; GARS_N; 1.
DR   SMART; SM01210; GARS_C; 1.
DR   SUPFAM; SSF51246; SSF51246; 1.
DR   SUPFAM; SSF52440; SSF52440; 1.
DR   SUPFAM; SSF53328; SSF53328; 1.
DR   SUPFAM; SSF55326; SSF55326; 1.
DR   SUPFAM; SSF56042; SSF56042; 1.
DR   TIGRFAMs; TIGR00877; purD; 1.
DR   TIGRFAMs; TIGR00878; purM; 1.
DR   TIGRFAMs; TIGR00639; PurN; 1.
DR   PROSITE; PS50975; ATP_GRASP; 1.
DR   PROSITE; PS00184; GARS; 1.
DR   PROSITE; PS00373; GART; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Ligase; Manganese; Metal-binding;
KW   Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Purine biosynthesis; Reference proteome; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1010       Trifunctional purine biosynthetic protein
FT                                adenosine-3.
FT                                /FTId=PRO_0000074937.
FT   DOMAIN      111    318       ATP-grasp.
FT   NP_BIND     137    199       ATP. {ECO:0000250}.
FT   REGION      434    809       AIRS.
FT   REGION      810   1010       GART.
FT   REGION      818    820       5'-phosphoribosylglycinamide binding.
FT   REGION      896    899       10-formyltetrahydrofolate binding.
FT   REGION      947    951       10-formyltetrahydrofolate binding.
FT   REGION      977    980       5'-phosphoribosylglycinamide binding.
FT   ACT_SITE    915    915       Proton donor. {ECO:0000250}.
FT   METAL       288    288       Manganese. {ECO:0000250}.
FT   METAL       290    290       Manganese. {ECO:0000250}.
FT   BINDING     871    871       10-formyltetrahydrofolate.
FT   BINDING     913    913       10-formyltetrahydrofolate.
FT   SITE        951    951       Raises pKa of active site His.
FT                                {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      10     10       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     350    350       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     440    440       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     682    682       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     796    796       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     802    802       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     434   1010       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005517.
FT   VARIANT      21     21       L -> F (in dbSNP:rs1804387).
FT                                /FTId=VAR_011817.
FT   VARIANT     421    421       V -> I (in dbSNP:rs8788).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:9224613}.
FT                                /FTId=VAR_011818.
FT   VARIANT     510    510       D -> G (in dbSNP:rs35927582).
FT                                /FTId=VAR_051882.
FT   VARIANT     641    641       P -> A (in dbSNP:rs34588874).
FT                                /FTId=VAR_051883.
FT   VARIANT     752    752       D -> G (in dbSNP:rs8971).
FT                                /FTId=VAR_011819.
FT   STRAND        2      9       {ECO:0000244|PDB:2QK4}.
FT   HELIX        12     21       {ECO:0000244|PDB:2QK4}.
FT   STRAND       27     34       {ECO:0000244|PDB:2QK4}.
FT   HELIX        37     39       {ECO:0000244|PDB:2QK4}.
FT   STRAND       40     47       {ECO:0000244|PDB:2QK4}.
FT   HELIX        55     65       {ECO:0000244|PDB:2QK4}.
FT   STRAND       69     72       {ECO:0000244|PDB:2QK4}.
FT   HELIX        76     79       {ECO:0000244|PDB:2QK4}.
FT   HELIX        82     88       {ECO:0000244|PDB:2QK4}.
FT   STRAND       93     95       {ECO:0000244|PDB:2QK4}.
FT   TURN         98    101       {ECO:0000244|PDB:2QK4}.
FT   HELIX       102    105       {ECO:0000244|PDB:2QK4}.
FT   HELIX       107    116       {ECO:0000244|PDB:2QK4}.
FT   STRAND      124    129       {ECO:0000244|PDB:2QK4}.
FT   HELIX       130    139       {ECO:0000244|PDB:2QK4}.
FT   STRAND      144    151       {ECO:0000244|PDB:2QK4}.
FT   STRAND      158    160       {ECO:0000244|PDB:2QK4}.
FT   HELIX       164    174       {ECO:0000244|PDB:2QK4}.
FT   STRAND      187    191       {ECO:0000244|PDB:2QK4}.
FT   STRAND      195    204       {ECO:0000244|PDB:2QK4}.
FT   STRAND      209    211       {ECO:0000244|PDB:2QK4}.
FT   STRAND      215    222       {ECO:0000244|PDB:2QK4}.
FT   TURN        223    225       {ECO:0000244|PDB:2QK4}.
FT   STRAND      226    238       {ECO:0000244|PDB:2QK4}.
FT   HELIX       244    253       {ECO:0000244|PDB:2QK4}.
FT   HELIX       255    264       {ECO:0000244|PDB:2QK4}.
FT   STRAND      271    280       {ECO:0000244|PDB:2QK4}.
FT   STRAND      283    292       {ECO:0000244|PDB:2QK4}.
FT   TURN        295    297       {ECO:0000244|PDB:2QK4}.
FT   HELIX       298    301       {ECO:0000244|PDB:2QK4}.
FT   HELIX       302    304       {ECO:0000244|PDB:2QK4}.
FT   HELIX       309    317       {ECO:0000244|PDB:2QK4}.
FT   HELIX       321    324       {ECO:0000244|PDB:2QK4}.
FT   STRAND      333    340       {ECO:0000244|PDB:2QK4}.
FT   TURN        342    345       {ECO:0000244|PDB:2QK4}.
FT   HELIX       357    362       {ECO:0000244|PDB:2QK4}.
FT   STRAND      366    375       {ECO:0000244|PDB:2QK4}.
FT   STRAND      378    381       {ECO:0000244|PDB:2QK4}.
FT   STRAND      383    395       {ECO:0000244|PDB:2QK4}.
FT   HELIX       396    409       {ECO:0000244|PDB:2QK4}.
FT   HELIX       423    428       {ECO:0000244|PDB:2QK4}.
FT   TURN        479    483       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      485    494       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       499    506       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       512    525       {ECO:0000244|PDB:2V9Y}.
FT   TURN        526    528       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      530    542       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       545    562       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      565    573       {ECO:0000244|PDB:2V9Y}.
FT   TURN        575    577       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      583    594       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       595    597       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       602    604       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      610    615       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      617    619       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       624    633       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      648    650       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       651    655       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       663    671       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      677    680       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       685    689       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       691    693       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      698    703       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       704    706       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       711    720       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       724    730       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      735    741       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       743    745       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       746    755       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      760    768       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      776    779       {ECO:0000244|PDB:2V9Y}.
FT   HELIX       781    785       {ECO:0000244|PDB:2V9Y}.
FT   STRAND      809    816       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       819    828       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      836    844       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       848    855       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      860    862       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       865    867       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      868    870       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       871    884       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      888    894       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       901    906       {ECO:0000244|PDB:4ZZ1}.
FT   TURN        907    909       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      910    917       {ECO:0000244|PDB:4ZZ1}.
FT   TURN        919    922       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       927    934       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      937    945       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      955    962       {ECO:0000244|PDB:4ZZ1}.
FT   HELIX       969    992       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND      995    998       {ECO:0000244|PDB:4ZZ1}.
FT   STRAND     1002   1006       {ECO:0000244|PDB:4ZZ1}.
SQ   SEQUENCE   1010 AA;  107767 MW;  9A4213F746EB17A2 CRC64;
     MAARVLIIGS GGREHTLAWK LAQSHHVKQV LVAPGNAGTA CSEKISNTAI SISDHTALAQ
     FCKEKKIEFV VVGPEAPLAA GIVGNLRSAG VQCFGPTAEA AQLESSKRFA KEFMDRHGIP
     TAQWKAFTKP EEACSFILSA DFPALVVKAS GLAAGKGVIV AKSKEEACKA VQEIMQEKAF
     GAAGETIVIE ELLDGEEVSC LCFTDGKTVA PMPPAQDHKR LLEGDGGPNT GGMGAYCPAP
     QVSNDLLLKI KDTVLQRTVD GMQQEGTPYT GILYAGIMLT KNGPKVLEFN CRFGDPECQV
     ILPLLKSDLY EVIQSTLDGL LCTSLPVWLE NHTALTVVMA SKGYPGDYTK GVEITGFPEA
     QALGLEVFHA GTALKNGKVV THGGRVLAVT AIRENLISAL EEAKKGLAAI KFEGAIYRKD
     VGFRAIAFLQ QPRSLTYKES GVDIAAGNML VKKIQPLAKA TSRSGCKVDL GGFAGLFDLK
     AAGFKDPLLA SGTDGVGTKL KIAQLCNKHD TIGQDLVAMC VNDILAQGAE PLFFLDYFSC
     GKLDLSVTEA VVAGIAKACG KAGCALLGGE TAEMPDMYPP GEYDLAGFAV GAMERDQKLP
     HLERITEGDV VVGIASSGLH SNGFSLVRKI VAKSSLQYSS PAPDGCGDQT LGDLLLTPTR
     IYSHSLLPVL RSGHVKAFAH ITGGGLLENI PRVLPEKLGV DLDAQTWRIP RVFSWLQQEG
     HLSEEEMART FNCGVGAVLV VSKEQTEQIL RDIQQHKEEA WVIGSVVARA EGSPRVKVKN
     LIESMQINGS VLKNGSLTNH FSFEKKKARV AVLISGTGSN LQALIDSTRE PNSSAQIDIV
     ISNKAAVAGL DKAERAGIPT RVINHKLYKN RVEFDSAIDL VLEEFSIDIV CLAGFMRILS
     GPFVQKWNGK MLNIHPSLLP SFKGSNAHEQ ALETGVTVTG CTVHFVAEDV DAGQIILQEA
     VPVKRGDTVA TLSERVKLAE HKIFPAALQL VASGTVQLGE NGKICWVKEE
//
